Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal antibody

Clinical Cancer Research

Volumn 5, Issue 10 SUPPL., 1999, Pages

  Wiseman, Gregory A ^a   White, Christine A ^b   Witzig, Thomas E ^a   Gordon, Leo I ^c   Emmanouilides, Christos ^d   Raubitschek, Andrew ^e   Janakiraman, Nalini ^f   Gutheil, John ^g   Schilder, Russell J ^h   Spies, Stewart ^c   Silverman, Daniel H S ^d   Grillo López, Antonio J ^b  

^a MAYO CLINIC   (United States)

^b BIOGEN   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f HENRY FORD HOSPITAL   (United States)

^g SIDNEY KIMMEL CANCER CENTER   (United States)

^h FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CHELATING AGENT; EDETIC ACID; IBRITUMOMAB; IBRITUMOMAB TIUXETAN; IODINE 131; MONOCLONAL ANTIBODY; PENTETIC ACID; RITUXIMAB; UNCLASSIFIED DRUG; YTTRIUM 90;

ANTIBODY RESPONSE; BLOOD TOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DOSIMETRY; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; RELAPSE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; HUMANS; LYMPHOMA, NON-HODGKIN; PENTETIC ACID; RADIOIMMUNOTHERAPY; RECURRENCE; YTTRIUM RADIOISOTOPES;

EID: 0032748607     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Grossbard, M., and Nadler, L. Monoclonal antibody therapy for indolent lymphomas. Semin. Oncol., 20: 118-135, 1993.
2. Grossbard, M., Press, O., Appelbaum, F., Bernstein, I., and Nadler, L. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood, 80: 863-878, 1992.
3. Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., and Anderson, D. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood, 83: 435-445, 1994.
4. Newman, R., Alberts, J., Anderson, D., Carner, K., Heard, C., Norton, F., et al. "Primatization" of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4. Biotechnology, 10: 1455-1460, 1992.
5. LoBuglio, A., Wheeler, R., Trang, J., Haynes, A., Rogers, K., Harvey, E., Sun, L., Ghrayeb, J., and Khazeli, M. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA. 86: 4220-4224, 1989.
6. Colnaghi, M. Generation of monoclonal antibodies for in vivo approaches. Nucl. Med. Biol., 18: 15-18, 1991.
7. Juweid, M., Sharkey, R., Markowitz, A., Behr, T., Swayne, L., Dunn, R., Hansen, H. J., Shevitz, J., Leung, S-D., Rubin, A. D., Herskovic, T., Hanley, D., and Goldenberg, D. M. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res., 55: 5899s-5907s, 1995.
8. Maloney, D., Smith, B., and Appelbaum, F. The anti-tumor effect of monoclonal anti-CD20 antibody (MAB) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood, 88: 637a, 1996.
9. Press, O., Early, J., Badger, C., Martin, P., Appelbaum, F., Levy, R., Miller, R., Brown, S., Nelf, W. B., Krohn, K. A., Fisher, D., DeSantes, K., Porter, B., Kidd, P., Thomas, D., and Bernstein, I. D. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J. Clin. Oncol., 7: 1027-1038, 1989.
10. Epstein, A., Marder, R., Winter, J., Stathopoulos, E., Chen, F-M., Parker, J., and Taylor, C. R. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res., 47: 830-840, 1987.
11. Stein, R., Belisle, E., Hansen, H. J., and Goldenberg, D. M. Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2. Cancer Immunol. Immunother., 37: 293-298, 1993.
12. Goldenberg, D., Horowitz, J., Sharkey, R., Hall, T., Murthy, S., Goldenberg, H., Lee, R. E., Stein, R., Siegel, J. A., Izon, D. O., Burger, K., Swayne, L. C., Belisle, E., Hansen, H. J., and Pinsky, C. M. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J. Clin. Oncol., 9: 548-564, 1991.
13. Vitetta, E. S., Stone, M., Amlot, P., Fay, J., May, R., Till, M., Newman, J., Clark, P., Collins, R., Cunningham, D., Ghetie, V., Uhr, J. W., and Thrope, D. E. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res., 51: 4052-4058, 1991.
14. Grossbard, M., Freedman, A., Ritz, J., Coral, F., Goldmacher, V., Eliseo, L., Spector, N., Dear, K., Lambert, J. M., Blattner, W. A., Taylor, J. A., and Nadler, L. M. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a Phase I trial of daily bolus infusion. Blood, 79: 576-585, 1992.
15. Knox, S., Goris, M., Trisler, K., Negrin, R., Davis. T., Liles, T-M., Grillo-López, A. J., Chinn, P., Varns, C., Ning, S-C., Fowler, S., Deb, N., Becker, M., Marquez, C., and Levy, R. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res., 2: 457-470, 1996.
16. Witzig, T., White, C., Wiseman, G., Gordon, L., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Spies, S., Silverman, D., Gutheil, J., Schilder, R. J., Ding, E., Shen, D., and Grillo-López, A. J. IDEC-Y2B8 radioimmunotherapy: responses in patients with splenomegaly. Blood, 92: 417a, 1998.
17. Press, O., Eary, J., Appelbaum, F., Martin, P., Badger, C., Nelp, W., Glenn, S., Butshko, G., Fisher, D., Porter, B., Matthews, D. C., Fisher, L. D., and Bernstein, I. D. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med., 329: 1219-1224, 1993.
18. Kaminski, M., Zasadny, K., Francis, I., Fenner, M., Ross, C., Milik, A., Estes, J., Tuck, M., Regan, D., Fisher, S., Glenn, S. D., and Wahl, R. L. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol., 14: 1974-1981, 1996.
19. McLaughlin, P., Grillo-López, A., Maloney, D., Link, B., Levy, R., Czuczman, M., Cabanillas, F., Dallaire, B. K., and White, C. A. Efficacy controls in long-term follow-up of patients treated with Rituximab for relapsed or refractory, low-grade or follicular NHL. Blood, 92: 414a-415a, 1998.
20. Anderson, K., Bates, M., Slaughenhoupt, B., Pinkus, G., Schlossman, S., and Nadler, L. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood, 63: 1424-1433, 1984.
21. Stashenko, P., Nadler, L., Hardy, R., and Schlossman, S. Characterization of a human B lymphocyte-specific antigen. J. Immunol., 125: 1678-1685, 1980.
22. McLaughlin, P., Grillo-López, A., Link, B., Levy, R., Czuczman, M., Williams, M., Williams, M. E., Heyman, M. R., Bence-Brucker, I., White, C.A., Cabanillas, F., Jain, V., Ho, A. D., Lister, J., Wey, K., Shen, D., and Dallaire, B. K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a 4-dose treatment program. J. Clin. Oncol., 16: 2825-2833, 1998.
23. Press, O., Appelbaum, F., Ledbetter, J., Martin, P., Zarling, J., Kidd, P., and Thomas, E. D. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas. Blood, 69: 584-591, 1987.
24. Liu, A., Robinson, R., Murray, E., Jr., Ledbetter, J., Hellstroom, L. and Hellstrom, K. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J. Immunol., 139: 3521-3526, 1987.
25. Demidem, A., Lam, T., Alas, S., Hariharan. K., Hanna, N., and Bonavida, B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm., 12: 177-186, 1997.
26. Grillo-López, A., Cheson, B., Horning, S., Peterson, B., Carter, W., Varns, C., Shen, D., and Klippenstein, D. Response criteria for NHL: importance of "normal" lymph node size and correlations response. Blood, 92: 412a, 1998.
27. Halpern, S., Haindl, W., Beauregard, J., Hagan, P., Clutter, M., Amox, D., Merchant, B., Unger, M., Mongovi, C., Bartholomew, R., Jue, R., Carlo, D., and Dillman, R. Scintigraphy with In-111-labeled monoclonal antitumor antibodies: kinetics, biodistribution and tumor detection. Radiology, 168: 529-536, 1988.
28. Sutherland, R., Buchegger, F., Schreyer, M., Vacca, A., and Mach, J-P. Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids. Cancer Res., 47: 1627-1633, 1987.
29. Wiseman, G., Witzig, T., White, C., Grillo-López, A., Gordon. L., Emmanouilides, C., Raubitschek, A., Dunn, W., Chinn, P., Gutheil. J., Janakiraman, N., and Schieder, R. J. Radiommunotherapy of relapsed or refractory non-Hodgkin's lymphoma (NHL) with IDEC-Y2B8. In: Annual Scientific Conference ASTRO, pp. Phoenix, AZ: , 1998.
30. 90Y-hLL2 anti-CD22 MAB in patients with B-cell malignancies. Cancer Biother. Radiopharm., 13: 302, 1998.
31. 131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med., 329: 459-465, 1993.
32. Ward, J. Biotechnology and nuclear medicine: radiology brings biotechnology into the picture to combat cancer. Advance for Radiologic Science Professionals, 11: 24-25, 108, 1998.
33. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody (MAb) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). Clin. Cancer Res., in press, 1999.
34. 90Y-labeled MAbs. Cancer Biother. Radiopharm., 14: 37-47, 1999.
35. 131I-labeled MAbs in the therapy of human lung cancer xenograft. Proc. Am. Assoc. Cancer Res., 38: 404, 1997.
36. 131I with "non-internalizing" monoclonal antibodies (MAbs). In: European Association of Nuclear Medicine, pp. Barcelona, Spain: 1999.
37. Rao, D., and Howell, R. Time-dose-fractionation in radioimmunotherapy: implications for selecting radionuclides. J. Nucl. Med., 34: 1801-1810, 1993.
38. 111In-labeled monoclonal antibody 96.5. Cancer Res., 45: 2376-2381, 1985.
39. Dillman, R., Beauregard, J., Ryan, K., Hagan, P., Clutter, M., Amox, D., Frincke, J. M., Bartholomew, R. M., Burnett, K. G., David, G. S., Carlo, D. J., and Halpern, S. E. Radioimmunodetection of cancer with the use of indium-111-labeled monoclonal antibodies. NCCI Monogr., 3: 33-36, 1987.
40. Lamki, L. The effect of increasing "cold" antibody dose on prostatic cancer metastases detection and on body distribution of PAY-276 monoclonal antibody. J. Nucl. Med., 27: 1021, 1986.
41. 111In-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma. Cancer Res., 45: 2382-2386, 1985.
42. Kozak, R., Raubitschek, A., Mirzadeh, S., Brechbiel, M., Junghaus, R., Gansow, O., and Waldmann, T. A. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Cancer Res., 49: 2639-2644, 1989.
43. Brechbiel, M., Gansow, O., Atcher, R., Schlom, J., Esteban, J., Simpson, D., and Colcher, D. Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies. Inorganic Chem., 25: 2772-2781, 1986.
44. Mirzadeh, S., Brechbiel, M., Atcher, R., and Gansow, O. Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentacetic acid ligands to immunoglobulin. Bioconjugate Chem., 1: 59-65, 1990.
45. 90Y radioimmunotherapy. Bioconjugate Chem., 2: 187-194, 1991.
46. Sharkey, R., Motta-Hennessy, C., Gansow, O., Brechbiel, M., Fand, I., and Griffiths, G. Selection of a DTPA chelate conjugate for monoclonal antibody targeting to a human colonic tumor in nude mice. Int. J. Cancer, 46: 79-85, 1990.
47. 90Y-labeled anti-CD20 monoclonal antibody conjugated to MX-DTPA, a high-affinity chelator for yttrium. In: AACR Annual Meeting, pp. Philadelphia, PA: , 1999.
48. 90yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): interim results of a Phase I/II trial. Blood, 90: 586a, 1997.
49. Witzig, T., White, C., Wiseman, G., Gordon, L., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Gutheil, J., Schilder, R. J., Silverman, D. H., Riley, M. B., Sklenar, T., and Grillo-López, A. J. Commonly used response criteria for non-Hodgkin's lymphoma (NHL) applied to IDEC-Y2B8 radioimmunotherapy trial: importance of "normal" lymph node size. Proc. Am. Soc. Clin. Oncol., 18: 41a, 1999.